the aid library

World Health Organization WHO (2021) C_WHO

Вариативные рекомендации 24 сентября 2021 г. Этот документ представляет собой текущие рекомендации ВОЗ. В них будут вноситься изменения и дополнения, касающиеся нов... more

Download (482)

View PDF (446)

COVID Reference 2021.6 EN
recommended

Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC

Download (175)

View PDF (245)

COVID-19 Scientific and Public Health Policy Update – (6 July 2022)

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.

Download (242)

View PDF (225)

Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration

E. J. Abrams; J. Ananworanich; M. Archary; M.N. Ngongondo; P. Brouwers J Acquir Immune Defic Syndr; Pub Med (2018) C2

J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018

Download (334)

View PDF (446)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (182)

View PDF (250)

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.

External Link

Management of severe paediatric malaria in resource-limited settings

Maitland, K. (2015)

BMC Medicine (2015) 13:42 DOI 10.1186/s12916-014-0263-6

Download (2066)

View PDF (2656)

Global Disease Detection (GDD) Manual “Rapid Diagnostic Tests for Epidemic Diseases”

Center for Disease Control Centers for Disease Control and Prevention (CDC) (2011) C_CDC

Download (791)

View PDF (1332)

Zika Virus Research Agenda - October 2016

World Health Organization WHO (2016) C_WHO

Download (318)

View PDF (521)

Responding to a poliovirus event or outbreak - Part 2: Protocol for poliovirus type 2

Global Polio Eradication Initiative WHO (2017) C_WHO

The main objectives of the SOPs are to: (i) establish standards and timelines for response activities; and (ii) guide national governments and GPEI partners in key support functions. This new version of the SOPs presents overall response requirements for dealing with type 1, 2 and 3 poliovirus fo... more

Download (507)

View PDF (1368)

Diphtheria vaccine: WHO position paper – August 2017. Vaccin antidiphtérique: Note de synthèse de l’OMS – août 2017

World Health Organization WHO (2017) C_WHO

Weekly epidemiological record/ Relevé épidémiologique hebdomadaire 4 AUGUST 2017, 92th YEAR / 4 AOÛT 2017, 417-436

Download (1640)

View PDF (6825)

Polio vaccines: WHO position paper – June 2022
recommended

World Health Organization WHO (2022) C_WHO

This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.

Download (288)

View PDF (493)

Responding to a poliovirus event or outbreak - Part 1: General SOPs

Global Polio Eradication Initiative WHO (2017) C_WHO

Responding to a poliovirus event and outbreak, Part 1: General (SOPs) describes the general principles and steps to facilitate timely and effective responses to poliovirus events and outbreaks, and incorporate lessons learned from recent previous outbreak response efforts. This document summarizes r... more

Download (165)

View PDF (198)

COVID References top 10 Daily Science. Vol.2 16 October to 23 October 2020

Hoffmann, C.; B.S. Kamps (2020) CC

There is no secret to our procedure: the daily scanning of the literature helps us to stay afloat in the never-ending waves of new publications about SARS-CoV-2 and COVID-19. Many papers discussed in the Top 10 will eventually make it into subsequent editions of COVID Reference.

Download (617)

View PDF (933)

National Guidelines for Implementation of Parasite Based Diagnosis of Malaria in Uganda

Ministry of Health, Uganda (2013) C1

Download (329)

View PDF (654)

When populism takes over the delivery of health care: Venezuela

Sunil Daryanani (2017) C1

Download (2369)

View PDF (6600)

Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation
recommended

World Health Organization (2014) C_WHO

Download (452)

View PDF (775)

Global influenza strategy 2019-2030

World Health Organization WHO (2019) C_WHO

The goal of the strategy is to prevent seasonal influenza, control the spread of influenza from animals to humans, and prepare for the next influenza pandemic. The new strategy is the most comprehensive and far-reaching that WHO has ever developed for influenza. It outlines a path to protect popul... more

Download (237)

View PDF (252)

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021

World Health Organization WHO (2022) C_WHO

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.

Download (328)

View PDF (164)

Fact sheet on Cervical Cancer

Cancer Association of South Africa (CANSA) (2021) CC

COVID Reference 2021.6 EN recommended

Polio vaccines: WHO position paper – June 2022 recommended

Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation recommended

COVID Reference 2021.6 EN
recommended

Polio vaccines: WHO position paper – June 2022
recommended

Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation
recommended